Browsing Category
Trending
MYM Nutraceuticals appoints Dr. Charith Adkar as its new Chief Science Officer
MYM Nutraceuticals appoints Dr. Charith Adkar as its Chief Science Officer effective immediately.
Dr. Adkar has pursued his PhD in Plant Biology and Crop Production from the…
Read More...
Read More...
PCMA conveys response to Scott Gottlieb’s comments on Biosimilars
The Pharmaceutical Care Management Association has issued the following response to the remarks made by the FDA Commissioner Scott Gottlieb.
The response issued was "In an era of…
Read More...
Read More...
FDA Commissioner Scott Gottlieb vows to commit to market review of Essure
FDA Commissioner, Scott Gottlieb affirmed that FDA vows to commit itself to addressing women's health issues by speaking directly to patients and their families about significant health…
Read More...
Read More...
Perrigo receives final approval from FDA for OTC equivalent of Mucinex DM
Perrigo Company asserted that it has received final approval from the U.S Food and Drug Administration for the store brand OTC equivalent of Muciinex DM Maximum Strength Guaifenesin and…
Read More...
Read More...
Veloxis submits sNDA to FDA seeking new indication for ENVARSUS XR
Veloxis Pharmaceuticals asserted that it has submitted a supplemental New Drug Application to the U.S Food and Drug Administration seeking new indication for ENVARSUS XR (tacrolimus…
Read More...
Read More...
Ligand signs license agreement with Roivant Sciences
Ligand Pharmaceuticals signed a license agreement extending Roivant sciences exclusive global rights to develop and commercialize LGD-6972, ligand's glucagon receptor antagonist.
As…
Read More...
Read More...
Biohaven enrolls first patient in Phase 3 Clinical Trial to assess Rimegepant Zydis ODT to treat…
Biohaven Pharmaceuticals asserted that it has enrolled the first patient in a Phase 3 Clinical Trial of Zydis that is a orally dissolving tablet formulation of rimegepant for the…
Read More...
Read More...
Apexigen and Pediatric Brain Tumor Consortium collaborate to evaluate APX005M in Brain tumor…
Apexigen which is clinical-stage bio pharmaceutical company and the Pediatric Brain Tumor Consortium (PBTC) announced a Clinical trial collaboration to assess and evaluate Apexigen's …
Read More...
Read More...
Citius Pharmaceuticals conveys progress in Hemorroid Treatment Program
Citius Pharmaceuticals which is a specialty pharmaceutical company announced that the Company is finalizing a higher potency corticosteroid in its steroid/anesthetic topical formulation…
Read More...
Read More...
Forendo Pharma appoints David Colpman as Non-executive Director to its board of directors
Forendo Pharma which is a drug development company developing novel oral treatments for endometriosis patients asserted the appointment of David Colpman as a Non-executive Director to…
Read More...
Read More...
FDA authorization extended to 23andMe for Direct-to Consumer Genetic Test on Cancer Risk
23andMe which is the leading personal genetics company received FDA Authorization for a direct-to-consumer genetic test for cancer risk.The authorization allows 23andMe to provide…
Read More...
Read More...
Theratechnologies states FDA approval of innovative therapy, Trogarzo Injection
Theratechnologies and its partner TaiMed Biologics, Inc. (TaiMed) asserted that the U.S. Food and Drug Administration (FDA) has granted approval of Trogarzo (ibalizumab-uiyk) Injection.…
Read More...
Read More...
FDA sanctions Trogarzo as HIV treatment for untreated patients
The U.S Food and Drug Administration has sanctioned Trogarzo which is a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications…
Read More...
Read More...
FDA sanctions AFIA for detecting antibodies to Babesia microti and Imugen Babesia microti NAT
The U.S Food and Drug Administration has sanctioned the Imugen Babesia microti Arrayed Fluorescent Immunoassay (AFIA), for the detection of antibodies to Babesia microti (B. microti) in…
Read More...
Read More...
Contego Medical commences enrollment in the PERFORMANCE I Trial
Contego Medical has affirmed the enrollment in the PERFORMANCE I Trial, a clinical trial designed to evaluate the safety and feasibility of the Neuroguard IEP 3-in-1 Carotid Stent and…
Read More...
Read More...
Magenta Therapeutics and Heidelberg Pharma sign agreement on Development of Antibody Drug Conjugates
Magenta Therapeutics which is a biotechnology company developing therapeutics to enhance and extend the use of curative bone marrow transplant for more patients and Heidelberg Pharma AG…
Read More...
Read More...
City of Hope scientists and doctors proclaim New drug to combat Chronic myelogenous leukemia
City of Hope scientists and doctors have discerned a more effective treatment for patients with Chronic myelogenous leukemia using a drug that was developed at the Institution to…
Read More...
Read More...
GlycoMimetics unveils design of Phase 3 Clinical Trial for GMI-1271 in Relapsed AML
GlycoMimetics unveiled design for a randomized, double blind, placebo-controlled Phase 3 Clinical Trial to evaluate GMI-1271 in combination with MEC (Mitoxantrone, etoposide and Ara-C)…
Read More...
Read More...
Sagent Pharmaceuticals asserted nationwide recall of Methylprednisolone Sodium Succinate for…
Sagent Pharmaceuticals asserted the voluntary nationwide recall of ten lots of Methylprednisolone Sodium Succinate for Injection, USP, 40mg, 125mg, and 1g. The products were…
Read More...
Read More...
Sinovac Biotech plans to enhance corporate governance
Sinovac Biotech which is a provider of bio-pharmaceutical products in China has plans to accentuate the corporate governance and management of Sinovac Biotech Co., Ltd, the main…
Read More...
Read More...